CD8A and neoplasm: Y111 could bridge the T cells and PD-L1 expressing tumor cells, and prompted fresh CD8+ T cell-mediated lysis of H358 cells but spared this effect on the fresh γδ T cells enriched from the same donors, which suggested that Y111 could bypass the anti-tumor capacity of the fresh Vγ2Vδ2 T cells.